ES2166748T3 - Represor multivalente de la funcion genica. - Google Patents

Represor multivalente de la funcion genica.

Info

Publication number
ES2166748T3
ES2166748T3 ES90109892T ES90109892T ES2166748T3 ES 2166748 T3 ES2166748 T3 ES 2166748T3 ES 90109892 T ES90109892 T ES 90109892T ES 90109892 T ES90109892 T ES 90109892T ES 2166748 T3 ES2166748 T3 ES 2166748T3
Authority
ES
Spain
Prior art keywords
viric
mutations
vhtl
rex
function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90109892T
Other languages
English (en)
Inventor
Helmut Bachmayer
Ernst Boehnlein
Bryan R Cullen
Warner C Greene
Joachim Hauber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Duke University
Original Assignee
Novartis AG
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898915602A external-priority patent/GB8915602D0/en
Priority claimed from GB898924396A external-priority patent/GB8924396D0/en
Application filed by Novartis AG, Duke University filed Critical Novartis AG
Application granted granted Critical
Publication of ES2166748T3 publication Critical patent/ES2166748T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

SE DESCRIBEN REPRESORES TRANSDOMINANTES DE EXPRESION FENOTIPICA DE GENES VIRICOS DERIVADOS DEL GEN "REV" PRODUCTO DE VIH-1 O DEL GEN "REX" PRODUCIDO POR EL VHTL-1 Y MUTACIONES GENETICAS CORRESPONDIENTES, QUE TIENEN LA CAPACIDAD DE REPRIMIR LA FUNCION REV EN VIH-1 Y/O LA FUNCION REX EN VHTL-I Y VHTL-II. SE HAN USADO ANALISIS DE EXPRESIONES DE GENES TRANSITORIOS DE UNA SERIE DE MUTACIONES DE ELIMINACIONES Y DE SIGNIFICADO ERRONEO. SE HA ENCONTRADO QUE ALGUNAS DE ESTAS MUTACIONES REPRIMEN TANTO LA FUNCION REV COMO LA REX Y SON POR ELLO ACTIVOS EN MAS DE UNA ESPECIE VIRICA. LAS MUTACIONES VIRICAS TRANSDOMINANTES REPRESENTAN UNA PROMESA DE UNA NUEVA CLASE DE AGENTES ANTI VIRICOS. SE PUEDEN USAR EXPRESIONES CELULARES DE ESTOS INHIBIDORES TRANSDOMINANTES TANTO EN INJERTOS TERAPEUTICOS COMO EN INMUNIZACION INTRACELULAR PARA PROTEGER CELULAS CONTRA LOS PERNICIOSOS EFECTOS DE VIRUS, COMO POR EJEMPLO LA INFECCION DEL VIH-1.
ES90109892T 1989-05-25 1990-05-23 Represor multivalente de la funcion genica. Expired - Lifetime ES2166748T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35687889A 1989-05-25 1989-05-25
GB898915602A GB8915602D0 (en) 1989-07-07 1989-07-07 Multivalent repressor of gene function
GB898924396A GB8924396D0 (en) 1989-10-30 1989-10-30 Multivalent repressor of gene function
US44267089A 1989-11-29 1989-11-29

Publications (1)

Publication Number Publication Date
ES2166748T3 true ES2166748T3 (es) 2002-05-01

Family

ID=27450368

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90109892T Expired - Lifetime ES2166748T3 (es) 1989-05-25 1990-05-23 Represor multivalente de la funcion genica.

Country Status (13)

Country Link
EP (1) EP0406557B1 (es)
JP (2) JP3126378B2 (es)
KR (1) KR100215949B1 (es)
AT (1) ATE207122T1 (es)
AU (2) AU648256B2 (es)
CA (1) CA2032158C (es)
DE (1) DE69033829T2 (es)
DK (1) DK0406557T3 (es)
ES (1) ES2166748T3 (es)
FI (1) FI110437B (es)
HU (2) HU217091B (es)
IL (1) IL94482A (es)
WO (1) WO1990014427A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2115622T5 (es) * 1990-10-17 2003-03-16 Us Health Clones moleculares de hiv-1 y usos de los mismos.
US5534408A (en) * 1993-09-24 1996-07-09 University Of Massachusetts Medical Center 2-deoxystreptamine aminoglycoside inhibition of HIV RRE/Rev binding
US5650306A (en) * 1993-06-07 1997-07-22 University Of Michigan Recombinant nucleic acids for inhibiting HIV gene expression
WO1995004546A1 (en) * 1993-08-06 1995-02-16 Kai Juhani Ernst Krohn Novel mutated human and simian immunodeficiency viruses and vaccines containing said viruses
US6228369B1 (en) 1993-12-13 2001-05-08 Transgene S.A. Composition of trans-dominant variants of viral proteins for obtaining an anti-viral effect
US5981258A (en) * 1993-12-13 1999-11-09 Transgene S.A. Composition of trans-dominant variants of viral proteins for obtaining an antiviral effect
FR2713651B1 (fr) * 1993-12-13 1996-04-19 Transgene Sa Nouvelle composition pour un effet antiviral.
US6221578B1 (en) 1996-01-26 2001-04-24 Virco N.V. Method of managing the chemotherapy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains
EP0914444A1 (en) 1996-06-06 1999-05-12 Novartis AG Vectors comprising sar elements
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
IL127038A0 (en) * 1996-06-06 1999-09-22 Novartis Ag Inhibition of hiv-1 replication by antisense rna expression
CA2355836A1 (en) * 1998-12-22 2000-06-29 Ppd Development, Lp Genetic suppressor elements against human immunodeficiency virus
AU2493300A (en) * 1999-01-06 2000-07-24 Regents Of The University Of California, The Modulation of hiv replication using sam68
US7300790B2 (en) 2003-01-23 2007-11-27 Iogenetics, Llc Transgenic animals expressing transdominant negative retroviral nucleic acids and proteins
JP5653549B1 (ja) 2014-05-30 2015-01-14 株式会社松風 イオン徐放性歯科用レジン系仮封材組成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935372A (en) * 1986-05-20 1990-06-19 Dana Farber Cancer Institute Art nucleotide segments, vectors, cell lines methods of preparation and use

Also Published As

Publication number Publication date
HUT56135A (en) 1991-07-29
AU5738890A (en) 1990-12-18
KR920701440A (ko) 1992-08-11
FI110437B (fi) 2003-01-31
JP3126378B2 (ja) 2001-01-22
IL94482A0 (en) 1991-03-10
JPH10165188A (ja) 1998-06-23
KR100215949B1 (ko) 1999-08-16
ATE207122T1 (de) 2001-11-15
EP0406557A3 (en) 1991-05-02
DK0406557T3 (da) 2002-02-11
IL94482A (en) 2003-09-17
FI910371A0 (fi) 1991-01-24
EP0406557A2 (en) 1991-01-09
DE69033829D1 (de) 2001-11-22
DE69033829T2 (de) 2002-04-04
WO1990014427A3 (en) 1991-01-10
AU6757394A (en) 1994-11-17
JP3159671B2 (ja) 2001-04-23
HU904245D0 (en) 1991-06-28
EP0406557B1 (en) 2001-10-17
CA2032158C (en) 2009-09-15
AU648256B2 (en) 1994-04-21
JPH04500009A (ja) 1992-01-09
WO1990014427A2 (en) 1990-11-29
HU217091B (hu) 1999-11-29
AU678478B2 (en) 1997-05-29
HU211530A9 (en) 1995-11-28
CA2032158A1 (en) 1990-11-26

Similar Documents

Publication Publication Date Title
ES2166748T3 (es) Represor multivalente de la funcion genica.
Pomerantz et al. Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency
Fadel et al. TALEN knockout of the PSIP1 gene in human cells: analyses of HIV-1 replication and allosteric integrase inhibitor mechanism
Ng et al. IL-10: achieving balance during persistent viral infection
Bangham et al. Regulation of latency in the human T cell leukemia virus, HTLV-1
UY25869A1 (es) Moduladores de ccr5, formulaciones farmacéuticas, procedimientos y sus usos.
ES2139567T3 (es) Secuencias nucleotidicas procedentes del genoma de retrovirus del tipo vih-1 y sus aplicaciones para la amplificacion de los genomas de estos retrovirus y para el diagnostico in vitro de las infecciones producidas por estos virus.
ES2096343T3 (es) Oligonucleotido terapeutico anti-hiv y composicion farmaceutica.
ES2104717T3 (es) Oligonucleotidos para modular los efectos de las infecciones por citomegalovirus.
KR960703170A (ko) 안티센스 올리고뉴클레오티드 및 인간면역결핍바이러스감염에서 그것의 치료적이용(antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection)
ATE138384T1 (de) Olionukleotidalkylphosphonate und - phosphonothioate
DE69632256D1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
ES2140418T3 (es) Flavivirus quimericos y/o flavivirus de crecimiento restringido.
ES2058898T3 (es) Compuesto farmaceutico, util a titulo preventivo o curativo contra los tumores inducidos por los papilomavirus.
Mullins et al. Clonal expansion of human immunodeficiency virus–infected cells and human immunodeficiency virus persistence during antiretroviral therapy
Cevaal et al. Efficient mRNA delivery to resting T cells to reverse HIV latency
Lan et al. Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1–infected cells
ES2095241T3 (es) Secuencias oligonucleotidicas para la amplificacion del genoma de los retrovirus del tipo hiv-2 y siv, y sus aplicaciones al diagnostico in vitro de las infecciones debidas a estos virus.
Alfano et al. The binding subunit of pertussis toxin inhibits HIV replication in human macrophages and virus expression in chronically infected promonocytic U1 cells
Deruaz et al. Humanized mouse models of latent HIV infection
Casey et al. The functions of the HIV1 protein Vpr and its action through the DCAF1· DDB1· Cullin4 ubiquitin ligase
Seay et al. The vaginal acquisition and dissemination of HIV-1 infection in a novel transgenic mouse model is facilitated by coinfection with herpes simplex virus 2 and is inhibited by microbicide treatment
ATE188124T1 (de) Transformierte zellen zur verhütung oder zur behandlung von virus-induzierten erkrankungen,besonders pathogenen retroviren
Barnor et al. Intracellular expression of antisense RNA transcripts complementary to the human immunodeficiency virus type-1 vif gene inhibits viral replication in infected T-lymphoblastoid cells
HUP0100937A2 (hu) Többszörösen elágazó peptidkonstrukciókat tartalmazó liposzómák és alkalmazásuk humán immundeficiencia vírus ellen